Clinical trials: Urinary Bladder Diseases
Urinary Incontinence
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are…
- Trial name
- NCT00143377
- Testing
- tolterodine SR, overactive bladder
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in participants with overactive bladder and to guide…
- Trial name
- NCT01628042
- Testing
- Vibegron 100 mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910845
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 2 sites in United States, Canada
- Volunteers
- 557 people
- Sponsor
- Allergan
Urinary Bladder, Overactive
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
- Trial name
- NCT00645281
- Testing
- tolterodine extended release
- Where
- 96 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Interstitial Cystitis/Bladder Pain Syndrome
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
- Trial name
- NCT06285214
- Testing
- V117957
- Where
- 24 sites in United States
- Volunteers
- 47 people
- Sponsor
- Imbrium Therapeutics
Prostatic Hyperplasia, Urinary Bladder, Overactive
A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031
To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors UK369,003 and sildenafil
- Conditions
- Prostatic Hyperplasia, Urinary Bladder, Overactive, Erectile Dysfunction
- Trial name
- NCT00814736
- Testing
- UK369,003, sildenafil
- Where
- Singapore
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Urologic Neoplasms
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
- Trial name
- NCT00034593
- Testing
- ALIMTA, gemcitabine
- Where
- 9 sites in Finland, France and 1 more
- Sponsor
- Eli Lilly and Company
Urothelial Carcinoma
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are…
- Trial name
- NCT03171493
- Testing
- MV-NIS
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vyriad, Inc.
Urinary Incontinence, Urge, Urinary Bladder, Overactive
INTIBIA Pivotal Study
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
- Conditions
- Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- NCT05250908
- Testing
- INTIBIA Therapeutic, INTIBIA Non-Therapeutic
- Where
- 22 sites in United States, Netherlands
- Volunteers
- 208 people
- Sponsor
- Coloplast A/S
Bladder Cancer, Urothelial Carcinoma
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
- Trial name
- NCT05524545
- Testing
- Evorpacept, Enfortumab Vedotin
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- ALX Oncology Inc.
Urinary Bladder Neoplasms
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment…
- Trial name
- SNUGGLE (NCT05742867)
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Urinary Bladder, Overactive
Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy
Collect information on treatment with Toviaz (fesoterodine) under ordinary prescribing conditions, and to investigate whether additional educational information affects satisfaction with treatment as perceived by the patient.
- Trial name
- NCT01091519
- Testing
- Toviaz(fesoterodine) plus educational materials, Toviaz(fesoterodine) without educational materials
- Volunteers
- 781 people
- Sponsor
- Pfizer
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Overactive Bladder
Post Marketing Survey of Vesicare in Japan
This study is to evaluate the effect of Vesicare on quality of life (QOL) in female patients.
- Trial name
- SET-Q (NCT01489709)
- Testing
- Vesicare
- Where
- 8 sites in Japan
- Volunteers
- 1,160 people
- Sponsor
- Astellas Pharma Inc
Healthy Volunteer, Pharmacokinetics of YM178
A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers
The purpose of the study is to evaluate safety of YM178 and the effect of food intake on the pharmacokinetics of YM178 in healthy adult subjects.
- Trial name
- NCT01334905
- Testing
- YM178
- Where
- Taiwan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or…
- Trial name
- SunRISe-3 (NCT05714202)
- Testing
- TAR-200, Cetrelimab, BCG Vesiculture
- Where
- 240 sites in United States, Argentina and 19 more
- Volunteers
- 1,135 people
- Sponsor
- Janssen Research & Development, LLC
Urinary Incontinence, Urge Incontinence
UCon Treatment of Overactive Bladder (OAB) in Males
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired…
- Conditions
- Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT05874375
- Testing
- Urge stimulation, Time limited stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors.
- Conditions
- Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Trial name
- NCT04432857
- Testing
- AN0025, Pembrolizumab
- Where
- 6 sites in United States, France
- Volunteers
- 63 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Non Muscle Invasive Bladder Cancer, Bladder Cancer
Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
This is a Phase II, prospective, single-arm, open-label clinical study evaluating hyperthermic intravesical chemotherapy (HIVEC) with Mitomycin C in patients with high-grade, non-muscle-invasive bladder cancer (NMIBC) who are…
- Conditions
- Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder, Urinary Bladder Neoplasms
- Trial name
- HIVEC (NCT07231809)
- Testing
- Hyperthermic Intravesical Chemotherapy (HIVEC)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- AC.TA. S.r.l.